05/11/2026
We may not know how to cure cancer yet, but thanks to Dr. Jared Barrott and his work, we know a little bit more about how cancer cells mutate.
Researchers affiliated with Brigham Young University’s Simmons Center for Cancer Research have published a recent review article summarizing why we should care about cancer mutations that exist at a low frequency within a tumor. The study, “Hidden in the Noise: Low-Variant Allele Frequency Mutations and Their Impact on Precision Oncology,” appears in the Journal of Genome Biotechnology and Genetics and examines how preservation and sequencing techniques influence the detection of clinically relevant mutations. The study emphasizes the importance of low-variant allele frequency (low-VAF) mutations, which are often implicated in therapeutic resistance, metastasis, and recurrence. Improved detection of these low-frequency variants has been shown to expand treatment eligibility and enable earlier identification of disease progression. The researchers conclude that proper tissue handling and adaptive sequencing methods and bioinformatic pipelines provide superior molecular fidelity, supporting more accurate and comprehensive genomic profiling and enabling downstream functional analyses. These findings highlight a critical, yet underexamined, variable in precision oncology workflows and suggest that tissue handling at the point of resection may have long-term implications for both research and clinical outcomes to properly detect significant tumor mutations that are less abundant.
